Kiniksa Pharmaceuticals (KNSA) to Release Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is expected to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA opened at $20.02 on Friday. Kiniksa Pharmaceuticals has a 52-week low of $16.56 and a 52-week high of $28.15. The firm has a fifty day moving average of $19.71 and a 200 day moving average of $22.68. The firm has a market capitalization of $1.45 billion, a PE ratio of -142.99 and a beta of 0.32.

Insider Activity

In related news, COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00. Following the completion of the sale, the chief operating officer now directly owns 88,975 shares in the company, valued at approximately $1,622,904. This trade represents a 13.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Ragosa sold 8,969 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the sale, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This represents a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,092 shares of company stock valued at $745,589 in the last ninety days. Insiders own 54.57% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Evercore ISI raised their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, Wedbush restated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $36.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.